STOCK TITAN

Perceptive fund discloses 7% Aldeyra (ALDX) ownership stake

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Perceptive Advisors and affiliates report a 7.0% stake in Aldeyra Therapeutics, Inc. They beneficially own 4,185,632 shares of common stock, based on 60,162,773 shares outstanding as of November 4, 2025. The Perceptive Life Sciences Master Fund directly holds the shares, with Perceptive Advisors as investment manager and Joseph Edelman as managing member.

The reporting persons state that the securities were not acquired and are not held for the purpose of changing or influencing control of Aldeyra, consistent with a passive investment under Schedule 13G.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Perceptive Advisors LLC
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:02/17/2026
Joseph Edelman
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:02/17/2026
Perceptive Life Sciences Master Fund, Ltd.
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:02/17/2026

FAQ

What ownership in Aldeyra Therapeutics (ALDX) is reported by Perceptive Advisors?

Perceptive Advisors and related reporting persons disclose beneficial ownership of 4,185,632 Aldeyra common shares, representing 7.0% of the class. This percentage is calculated using 60,162,773 shares outstanding as of November 4, 2025, as referenced from Aldeyra’s Form 10-Q.

Which Perceptive entity directly holds Aldeyra Therapeutics (ALDX) shares?

The Perceptive Life Sciences Master Fund, Ltd. directly holds 4,185,632 shares of Aldeyra common stock. Perceptive Advisors serves as investment manager to this fund, and Joseph Edelman is the managing member of Perceptive Advisors, so each may be deemed to beneficially own the same shares.

How much voting and dispositive power do the Perceptive reporting persons have over Aldeyra (ALDX) shares?

Each reporting person reports 0 shares with sole voting or dispositive power and 4,185,632 shares with shared voting and shared dispositive power. This indicates decisions over these Aldeyra shares are made jointly rather than individually by any single reporting person.

Is Perceptive’s Aldeyra (ALDX) stake intended to influence control of the company?

The reporting persons certify the securities were not acquired and are not held for the purpose of changing or influencing control of Aldeyra. They also state the shares are not held in connection with any transaction having that purpose, other than activities tied to a specific nomination rule.

What date triggers this Aldeyra Therapeutics (ALDX) Schedule 13G/A amendment?

The reported date of the event requiring this ownership statement is December 31, 2025. Ownership percentages are based on Aldeyra’s 60,162,773 outstanding common shares as of November 4, 2025, as disclosed in its Quarterly Report on Form 10-Q filed November 5, 2025.

Who are the reporting persons in the Aldeyra Therapeutics (ALDX) Schedule 13G/A?

The filing identifies three reporting persons: Perceptive Advisors LLC, its managing member Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. All three report the same beneficial ownership amount and 7.0% percentage of Aldeyra’s common stock class.
Aldeyra Therapeu

NASDAQ:ALDX

ALDX Rankings

ALDX Latest News

ALDX Latest SEC Filings

ALDX Stock Data

317.66M
53.08M
Biotechnology
Pharmaceutical Preparations
Link
United States
LEXINGTON